Calibrating disease progression models using population data: A critical precursor to policy development in cancer control

Roman Gulati, Lurdes Inoue, Jeffrey Katcher, William Hazelton, Ruth Etzioni

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

There are many more strategies for early detection of cancer than can be evaluated with randomized trials. Consequently, model-projected outcomes under different strategies can be useful for developing cancer control policy provided that the projections are representative of the population. To project population-representative disease progression outcomes and to demonstrate their value in assessing competing early detection strategies, we implement a model linking prostate-specific antigen (PSA) levels and prostate cancer progression and calibrate it to disease incidence in the US population. PSA growth is linear on the logarithmic scale with a higher slope after disease onset and with random effects on intercepts and slopes; parameters are estimated using data from the Prostate Cancer Prevention Trial. Disease onset, metastatic spread, and clinical detection are governed by hazard functions that depend on age or PSA levels; parameters are estimated by comparing projected incidence under observed screening and biopsy patterns with incidence observed in the Surveillance, Epidemiology, and End Results registries. We demonstrate implications of the model for policy development by projecting early detections, overdiagnoses, and mean lead times for PSA cutoffs 4.0 and 2.5 ng/mL and for screening ages 50-74 or 50-84. The calibrated model validates well, quantifies the tradeoffs involved across policies, and indicates that PSA screening with cutoff 4.0 ng/mL and screening ages 50-74 performs best in terms of overdiagnoses per early detection. The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy.

Original languageEnglish (US)
Pages (from-to)707-719
Number of pages13
JournalBiostatistics
Volume11
Issue number4
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Policy Making
Prostate-Specific Antigen
Population Model
Progression
Precursor
Screening
Disease Progression
Cancer
Incidence
Prostate Cancer
Population
Control Policy
Neoplasms
Slope
Prostatic Neoplasms
Randomized Trial
Model
Hazard Function
Intercept
Epidemiology

Keywords

  • Decision analysis
  • Population health
  • Prostatic neoplasm
  • Screening

ASJC Scopus subject areas

  • Medicine(all)
  • Statistics and Probability
  • Statistics, Probability and Uncertainty

Cite this

Calibrating disease progression models using population data : A critical precursor to policy development in cancer control. / Gulati, Roman; Inoue, Lurdes; Katcher, Jeffrey; Hazelton, William; Etzioni, Ruth.

In: Biostatistics, Vol. 11, No. 4, 01.10.2010, p. 707-719.

Research output: Contribution to journalArticle

Gulati, Roman ; Inoue, Lurdes ; Katcher, Jeffrey ; Hazelton, William ; Etzioni, Ruth. / Calibrating disease progression models using population data : A critical precursor to policy development in cancer control. In: Biostatistics. 2010 ; Vol. 11, No. 4. pp. 707-719.
@article{d41ca0793c8f4f1381c83b7deeb52cd4,
title = "Calibrating disease progression models using population data: A critical precursor to policy development in cancer control",
abstract = "There are many more strategies for early detection of cancer than can be evaluated with randomized trials. Consequently, model-projected outcomes under different strategies can be useful for developing cancer control policy provided that the projections are representative of the population. To project population-representative disease progression outcomes and to demonstrate their value in assessing competing early detection strategies, we implement a model linking prostate-specific antigen (PSA) levels and prostate cancer progression and calibrate it to disease incidence in the US population. PSA growth is linear on the logarithmic scale with a higher slope after disease onset and with random effects on intercepts and slopes; parameters are estimated using data from the Prostate Cancer Prevention Trial. Disease onset, metastatic spread, and clinical detection are governed by hazard functions that depend on age or PSA levels; parameters are estimated by comparing projected incidence under observed screening and biopsy patterns with incidence observed in the Surveillance, Epidemiology, and End Results registries. We demonstrate implications of the model for policy development by projecting early detections, overdiagnoses, and mean lead times for PSA cutoffs 4.0 and 2.5 ng/mL and for screening ages 50-74 or 50-84. The calibrated model validates well, quantifies the tradeoffs involved across policies, and indicates that PSA screening with cutoff 4.0 ng/mL and screening ages 50-74 performs best in terms of overdiagnoses per early detection. The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy.",
keywords = "Decision analysis, Population health, Prostatic neoplasm, Screening",
author = "Roman Gulati and Lurdes Inoue and Jeffrey Katcher and William Hazelton and Ruth Etzioni",
year = "2010",
month = "10",
day = "1",
doi = "10.1093/biostatistics/kxq036",
language = "English (US)",
volume = "11",
pages = "707--719",
journal = "Biostatistics",
issn = "1465-4644",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Calibrating disease progression models using population data

T2 - A critical precursor to policy development in cancer control

AU - Gulati, Roman

AU - Inoue, Lurdes

AU - Katcher, Jeffrey

AU - Hazelton, William

AU - Etzioni, Ruth

PY - 2010/10/1

Y1 - 2010/10/1

N2 - There are many more strategies for early detection of cancer than can be evaluated with randomized trials. Consequently, model-projected outcomes under different strategies can be useful for developing cancer control policy provided that the projections are representative of the population. To project population-representative disease progression outcomes and to demonstrate their value in assessing competing early detection strategies, we implement a model linking prostate-specific antigen (PSA) levels and prostate cancer progression and calibrate it to disease incidence in the US population. PSA growth is linear on the logarithmic scale with a higher slope after disease onset and with random effects on intercepts and slopes; parameters are estimated using data from the Prostate Cancer Prevention Trial. Disease onset, metastatic spread, and clinical detection are governed by hazard functions that depend on age or PSA levels; parameters are estimated by comparing projected incidence under observed screening and biopsy patterns with incidence observed in the Surveillance, Epidemiology, and End Results registries. We demonstrate implications of the model for policy development by projecting early detections, overdiagnoses, and mean lead times for PSA cutoffs 4.0 and 2.5 ng/mL and for screening ages 50-74 or 50-84. The calibrated model validates well, quantifies the tradeoffs involved across policies, and indicates that PSA screening with cutoff 4.0 ng/mL and screening ages 50-74 performs best in terms of overdiagnoses per early detection. The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy.

AB - There are many more strategies for early detection of cancer than can be evaluated with randomized trials. Consequently, model-projected outcomes under different strategies can be useful for developing cancer control policy provided that the projections are representative of the population. To project population-representative disease progression outcomes and to demonstrate their value in assessing competing early detection strategies, we implement a model linking prostate-specific antigen (PSA) levels and prostate cancer progression and calibrate it to disease incidence in the US population. PSA growth is linear on the logarithmic scale with a higher slope after disease onset and with random effects on intercepts and slopes; parameters are estimated using data from the Prostate Cancer Prevention Trial. Disease onset, metastatic spread, and clinical detection are governed by hazard functions that depend on age or PSA levels; parameters are estimated by comparing projected incidence under observed screening and biopsy patterns with incidence observed in the Surveillance, Epidemiology, and End Results registries. We demonstrate implications of the model for policy development by projecting early detections, overdiagnoses, and mean lead times for PSA cutoffs 4.0 and 2.5 ng/mL and for screening ages 50-74 or 50-84. The calibrated model validates well, quantifies the tradeoffs involved across policies, and indicates that PSA screening with cutoff 4.0 ng/mL and screening ages 50-74 performs best in terms of overdiagnoses per early detection. The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy.

KW - Decision analysis

KW - Population health

KW - Prostatic neoplasm

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77953172727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953172727&partnerID=8YFLogxK

U2 - 10.1093/biostatistics/kxq036

DO - 10.1093/biostatistics/kxq036

M3 - Article

C2 - 20530126

AN - SCOPUS:77953172727

VL - 11

SP - 707

EP - 719

JO - Biostatistics

JF - Biostatistics

SN - 1465-4644

IS - 4

ER -